1. Home
  2. BOLD vs COEP Comparison

BOLD vs COEP Comparison

Compare BOLD & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • COEP
  • Stock Information
  • Founded
  • BOLD 2018
  • COEP 2017
  • Country
  • BOLD United States
  • COEP United States
  • Employees
  • BOLD N/A
  • COEP N/A
  • Industry
  • BOLD
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BOLD
  • COEP Health Care
  • Exchange
  • BOLD Nasdaq
  • COEP Nasdaq
  • Market Cap
  • BOLD 24.4M
  • COEP 27.4M
  • IPO Year
  • BOLD 2024
  • COEP N/A
  • Fundamental
  • Price
  • BOLD $1.19
  • COEP $11.16
  • Analyst Decision
  • BOLD Buy
  • COEP
  • Analyst Count
  • BOLD 3
  • COEP 0
  • Target Price
  • BOLD $4.00
  • COEP N/A
  • AVG Volume (30 Days)
  • BOLD 105.5K
  • COEP 56.9K
  • Earning Date
  • BOLD 08-11-2025
  • COEP 08-15-2025
  • Dividend Yield
  • BOLD N/A
  • COEP N/A
  • EPS Growth
  • BOLD N/A
  • COEP N/A
  • EPS
  • BOLD N/A
  • COEP N/A
  • Revenue
  • BOLD N/A
  • COEP $62,874.00
  • Revenue This Year
  • BOLD N/A
  • COEP N/A
  • Revenue Next Year
  • BOLD N/A
  • COEP N/A
  • P/E Ratio
  • BOLD N/A
  • COEP N/A
  • Revenue Growth
  • BOLD N/A
  • COEP N/A
  • 52 Week Low
  • BOLD $1.00
  • COEP $2.31
  • 52 Week High
  • BOLD $4.72
  • COEP $13.70
  • Technical
  • Relative Strength Index (RSI)
  • BOLD N/A
  • COEP 59.53
  • Support Level
  • BOLD N/A
  • COEP $11.30
  • Resistance Level
  • BOLD N/A
  • COEP $12.71
  • Average True Range (ATR)
  • BOLD 0.00
  • COEP 0.89
  • MACD
  • BOLD 0.00
  • COEP 0.18
  • Stochastic Oscillator
  • BOLD 0.00
  • COEP 54.39

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Share on Social Networks: